(no title)
Fordec | 6 months ago
Links to an article from 2017 about a tax loophole that was closed in 2020 [0]. As an Economist that by his Wikipedia article [1] dedicates so much of his time talking about the Irish tax regime, he should be well aware of this fact.
[0] https://budgetmodel.wharton.upenn.edu/issues/2024/10/14/the-... [1] https://en.wikipedia.org/wiki/Brad_W._Setser
muststopmyths|6 months ago
The link under your quoted line in the TFA seems to be talking about Apple (and others) preparing for the end of the Double Irish by finding other tax havens.
"Elite tax advisers help Apple Inc. and other corporate giants skirt impacts of crackdown on 'Double Irish' maneuvers."
So, I don't see what's invalid about the TFA's point, which is about tax avoidance in general
cowsandmilk|6 months ago
refurb|6 months ago
As someone close to pharmaceutical manufacturing, the reason why the manufacturing is done in Ireland is for tax benefits for sales in Europe.
So why not have a US factory for US sales? Because it's much more expensive and complex to have two separate factories making the same drug. It's far easier to just scale the Irish factory to serve all global sales.
Even the same companies with Irish factories have US factories as well. It's not like any tax benefit moved that out of the US as well.
kgwgk|6 months ago
If Pfizer operates in the US at a loss (or at least they did in 2018-2020) and all the profits are booked elsewhere it was their choice.
https://www.finance.senate.gov/imo/media/doc/wyden_pfizer_in...
readthenotes1|6 months ago
Switzerland is a whole different matter, but such carelessness doesn't improve trust
dmurray|6 months ago
And then there's this:
> The top seven pharmaceutical companies are paying $10 billion or so in tax on their $70 billion in offshore profit. They are just paying all that tax abroad.
So these companies already pay 14% in corporate tax. In the US, they'd pay 21% headline rate, but with room for deductions (I can't find a good source for what they actually pay, but here's [2] a bad source putting the R&D deduction alone at $15b/year across the top 8 companies). This 21% changed from 35% in the 2017 act the article criticises, though some deductions were also reduced. So corporate tax can't be the main differentiator here.
It's nice, for balance, to see an article that says the problem with Trump is that he just isn't protectionist enough. But the arguments here don't hold up.
[0] https://www.efpia.eu/media/219735/efpia-pharmafigures2017_st...
[1] https://efpia.eu/media/2rxdkn43/the-pharmaceutical-industry-...
[2] https://americansfortaxfairness.org/drug-firms-fight-restore...